Trialbee inks deal with Acclinate in push for trial diversity

Trialbee, a patient enrollment company, inked a partnership deal with Acclinate in a push to accelerate wider patient diversity in clinical trials.

Under the partnership, Sweden-based Trialbee will get access to Acclinate’s NOWINCLUDED offering that engages diverse populations on health-related issues, the company said in a Dec. 13 press release.

Founded in 2020, Birmingham, Alabama-based Acclinate is a digital health company focused on diversifying clinical trials. Its e-DICT platform assigns a proprietary Participant Probability Index score to assess community members' willingness to participate in clinical research. Then, Trialbee’s Honey Omnichannel can refer interested participants to research sites.

“Acclinate’s approach with NOWINCLUDED is innovative and focuses on overcoming well-documented issues around trust within communities of color,” Matt Walz, Trialbee’s chief executive, said in the release. “When combined with the power of our Honey platform, we’re much better positioned to achieve more equitable clinical research.”

The two companies said lupus was chosen as the pilot indication for the collaboration.

Trialbee launched Honey Omnichannel in late November saying the inflammatory disease would be an initial focus due to its complexity and unique patient populations. Lupus disproportionately affects women who identify as African American, Hispanic, Asian and Native American.